114 related articles for article (PubMed ID: 38723157)
1. CYP1A2 Polymorphism and Drug Co-administration Affect the Blood Levels and Adverse Effects of Pirfenidone.
Yang X; Wei J; Yang Y; He Y; Guo L; He X; Zhang L; Chen L
Ther Drug Monit; 2024 May; ():. PubMed ID: 38723157
[TBL] [Abstract][Full Text] [Related]
2. Association between hypertension and coffee drinking based on CYP1A2 rs762551 single nucleotide polymorphism in Taiwanese.
Hou CC; Tantoh DM; Lin CC; Chen PH; Yang HJ; Liaw YP
Nutr Metab (Lond); 2021 Aug; 18(1):78. PubMed ID: 34391463
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers.
Song L; Du Q; Jiang X; Wang L
J Clin Pharm Ther; 2014 Apr; 39(2):204-9. PubMed ID: 24372004
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Laika B; Leucht S; Heres S; Schneider H; Steimer W
Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
6. Fast Screening Technology for Drug Emergency Management: Predicting Suspicious SNPs for ADR with Information Theory-based Models.
Liang Z; Liu J; Huang JX; Zeng X
Comb Chem High Throughput Screen; 2018; 21(2):93-99. PubMed ID: 29336255
[TBL] [Abstract][Full Text] [Related]
7. CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients.
Majam T; Sukasem C; Reungwetwattana T; Chansriwong P; Atasilp C; Trachu N; Thamrongjirapat T; Sukprasong R; Meanwatthana J
Front Pharmacol; 2023; 14():1222435. PubMed ID: 38026963
[No Abstract] [Full Text] [Related]
8. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.
Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K
Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
[TBL] [Abstract][Full Text] [Related]
10. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
[TBL] [Abstract][Full Text] [Related]
11. Quercetin significantly inhibits the metabolism of caffeine, a substrate of cytochrome P450 1A2 unrelated to CYP1A2*1C (-2964G>A) and *1F (734C>A) gene polymorphisms.
Xiao J; Huang WH; Peng JB; Tan ZR; Ou-Yang DS; Hu DL; Zhang W; Chen Y
Biomed Res Int; 2014; 2014():405071. PubMed ID: 25025048
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Vieira de Lara D; Zubiaur P; Koller D; Mejía G; Abad-Santos F
J Psychopharmacol; 2019 Apr; 33(4):522-531. PubMed ID: 30789308
[TBL] [Abstract][Full Text] [Related]
13. Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program.
Lancaster L; Morrison L; Auais A; Ding B; Iqbal A; Polman B; Flaherty KR
Pulm Ther; 2017 Dec; 3(2):317-325. PubMed ID: 32026347
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis.
Ma Z; Guo W; Gong T; Niu HJ; Wang RW; Jiang YG
Tumour Biol; 2014 Mar; 35(3):2253-7. PubMed ID: 24293373
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis.
Li H; Yang J; Chen S; Wang P; Yu X; Zhou Q; Zhang X; Zhang G
Front Pharmacol; 2022; 13():1055702. PubMed ID: 36523502
[TBL] [Abstract][Full Text] [Related]
16. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
Han XM; Ouyang DS; Chen XP; Shu Y; Jiang CH; Tan ZR; Zhou HH
Br J Clin Pharmacol; 2002 Nov; 54(5):540-3. PubMed ID: 12445035
[TBL] [Abstract][Full Text] [Related]
17.
Trujillo-Paolillo A; Salinas-Souza C; Dias-Oliveira I; Petrilli AS; Toledo SRC
J Adolesc Young Adult Oncol; 2020 Dec; 9(6):621-627. PubMed ID: 32298597
[No Abstract] [Full Text] [Related]
18. Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver.
Zhang Y; Sato R; Fukami T; Nakano M; Nakajima M
Xenobiotica; 2021 Dec; 51(12):1352-1359. PubMed ID: 34779706
[TBL] [Abstract][Full Text] [Related]
19. Functional single-nucleotide polymorphism (rs762551) in CYP1A2 gene affects white coffee intake in healthy 20- to 40-year-old adults.
Nikrandt G; Mikolajczyk-Stecyna J; Mlodzik-Czyzewska M; Chmurzynska A
Nutr Res; 2022 Sep; 105():77-81. PubMed ID: 35905656
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
